Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NKG2D CAR T-Cell
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : NKG2D CAR T-Cell
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 05, 2020
Lead Product(s) : Welgenaleucel
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Liaocheng People's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 22, 2019
Lead Product(s) : Welgenaleucel
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Liaocheng People's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable